Insights into the role of bioactivation mechanisms in the toxic events elicited by non-nucleoside reverse transcriptase inhibitors

Advances in Molecular Toxicology

Volumn 6, Issue , 2012, Pages 1-39

  Pereira, Sofia A ^a   Wanke, Riccardo ^b   Marques, M Matilde ^b   Monteiro, Emília C ^a   Antunes, Alexandra M M ^b  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b INSTITUTO SUPERIOR TÉCNICO   (Portugal)

Author keywords

Covalent adducts; Drug bioactivation; Efavirenz; Etravirine; HIV; Metabolism; Nevirapine; Non nucleoside reverse transcriptase inhibitor; Rilpivirine; Toxicity

Indexed keywords

EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; GLUTATHIONE; NEVIRAPINE; RILPIVIRINE; VIRUS RNA;

ANXIETY DISORDER; ARTICLE; BINDING AFFINITY; CANCER INCIDENCE; CD4 LYMPHOCYTE COUNT; DEPRESSION; DIZZINESS; DRUG ACTIVITY; DRUG HALF LIFE; DRUG TOXICITY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; ELECTROPHILICITY; ERYTHEMA MULTIFORME; GENE MUTATION; HALLUCINATION; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCIDENCE; LIPODYSTROPHY; LIVER CELL CARCINOMA; LIVER TOXICITY; MANIA; MEASLES LIKE RASH; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RASH; SKIN MANIFESTATION; SKIN TOXICITY; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; SUICIDAL BEHAVIOR; TOXIC EPIDERMAL NECROLYSIS;

EID: 84865355478     PISSN: 18720854     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-59389-4.00001-X     Document Type: Chapter

References (185)

1. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. The HIV outpatient study investigators declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 1998, 338:853-860.
2. Deeks S.G., Phillips A.N. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009, 338:a3172.
3. Kushnir V.A., Lewis W. Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals. Fertil. Steril. 2011, 96:546-552.
4. Uetrecht J. Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction. Drug Metab. Rev. 2006, 38:745-753.
5. Srivastava A., Maggs J.L., Antoine D.J., Williams D.P., Smith D.A., Park B.K. Role of reactive metabolites in drug-induced hepatotoxicity. Handbook of Experimental Pharmacology 2010, 196:165-194. Springer, Heidelberg. J. Uetrecht (Ed.).
6. Russmann S., Kullak-Ublick G.A., Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr. Med. Chem. 2009, 16:3041-3053.
7. Schnyder B., Pichler W.J. Mechanisms of drug-induced allergy. Mayo Clin. Proc. 2009, 84:268-272.
8. Park B.K., Laverty H., Srivastava A., Antoine D.J., Naisbitt D., Williams D.P. Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity. Chem. Biol. Interact. 2011, 192:30-36.
9. Rundle A. Carcinogen-DNA adducts as a biomarker for cancer risk. Mutat. Res. 2006, 600:23-36.
10. Esteban A., Pérez-Mateo M., Boix V., Gonźlez M., Portilla J., Mora A. Abnormalities in the metabolism of acetaminophen in patients infected with the human immunodeficiency virus (HIV). Methods Find. Exp. Clin. Pharmacol. 1997, 19:129-132.
11. Townsend D.M., Tew K.D., Tapiero H. The importance of glutathione in human disease. Biomed. Pharmacother. 2003, 57:145-155.
12. World Health Organization, WHO guidelines on HIV/AIDS. (accessed January 8, 2012). http://www.who.int/rpc/guidelines/hiv_aids/en/index.html.
13. Mehta U., Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity?. Lancet Infect. Dis. 2007, 7:733-738.
14. Powles T., Robinson D., Stebbing J., Shamash J., Nelson M., Gazzard B., Mandelia S., Møller H., Bower M. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J. Clin. Oncol. 2009, 27:884-890.
15. Fulco P.P., McNicholl I.R. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. Pharmacotherapy 2009, 29:281-294.
16. Das K., Clark A.D., Vinkers H.M., Kavash R.W., Lewi P.J., Daeyaert F., Ho C.Y., de Béthune M.-P., Ye H., Boyer P.L., Heeres J., Ludovici D.W., Lichtenstein M.A., Clark P., de Jonge M.R., Kukla M.J., Andries K., Hughes S.H., Koymans L.M.H., De Corte B., Pauwels R., Janssen P.A.J., Arnold E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47:2550-2560.
17. US Food and Drug Administration, Intelence (etravirine) 2009, (accessed January 8, 2012). http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm180579.htm.
18. Tibotec Pharmaceuticals, EDURANT (rilpivirine) prescribing information 2011, (accessed January 8, 2012). http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf.
19. Marseille E., Kahn J.G., Mmiro F., Guay L., Musoke P., Fowler M.G., Jackson J.B. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet 1999, 354:803-809.
20. Lallemant M., Jourdain G., Le Coeur S., Mary J.Y., Ngo-Giang-Huong N., Koetsawang S., Kanshana S., McInstosh K., Thaineua V. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N. Engl. J. Med. 2004, 351:217-228. Perinatal HIV Prevention Trial (Thailand) Investigators.
21. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection, August 16 (2010) 1-219. (accessed January 8, 2012). http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf.
22. Clotet B., van der Valk M., Negredo E., Reiss P. Impact of nevirapine on lipid metabolism. J. Acquir. Immune Defic. Syndr. 2003, 34:S79-S84.
23. Perinatal HIV Guidelines Working Group, Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States, April 29 (2009) 1-90. (accessed January 8, 2012). http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf.
24. Medrano J., Barreiro P., Tuma P., Vispo E., Labarga P., Blanco F., Soriano V. Risk for immune-mediated liver reactions by nevirapine revisited. AIDS Rev. 2008, 10:110-115.
25. Thompson M.A., Aberg J.A., Cahn P., Montaner J.S., Rizzardini G., Telenti A., Gatell J.M., Günthard H.F., Hammer S.M., Hirsch M.S., Jacobsen D.M., Reiss P., Richman D.D., Volberding P.A., Yeni P., Schooley R.T. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304:321-333. International AIDS Society-USA.
26. Pollard R.B., Robinson P., Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin. Ther. 1998, 20:1071-1092.
27. Warren K.J., Boxwell D.E., Kim N.Y., Drolet B.A. Nevirapine-associated Stevens-Johnson syndrome. Lancet 1998, 351:567.
28. Fagot J.P., Mockenhaupt M., Bouwes-Bavinck J.N., Naldi L., Viboud C., Roujeau J.C., EuroSCAR Study Group Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001, 15:1843-1848.
29. Sanne I., Mommeja-Marin H., Hinkle J., Bartlett J.A., Lederman M.M., Maartens G., Wakeford C., Shaw A., Quinn J., Gish R.G., Rousseau F. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J. Infect. Dis. 2005, 191:825-829.
30. Baylor M.S., Johann-Liang R. Hepatotoxicity associated with nevirapine use. J. Acquir. Immune Defic. Syndr. 2004, 35:538-539.
31. Ananworanich J., Moor Z., Siangphoe U., Chan J., Cardiello P., Duncombe C., Phanuphak P., Ruxrungtham K., Lange J., Cooper D.A. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 2005, 19:185-192.
32. Viramune (nevirapine), Dear healthcare professional letter 2000, (accessed January 2, 2012). http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175766.htm.
33. EMEA Public statement on Viramune (nevirapine), Severe and life-threatening cutaneous and hepatic reactions (EMEA/11260/00) 2000, (accessed January 2, 2012). http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2010/08/WC500095428.pdf.
34. Ho T.T., Wong K.H., Chan K.C., Lee S.S. High incidence of nevirapine-associated rash in HIV-infected Chinese. AIDS 1998, 12:2082-2083.
35. Bersoff-Matcha S.J., Miller W.C., Aberg J.A., Van Der Horst C., Hamrick H.J., Powderly W.G., Mundy L.M. Sex differences in nevirapine rash. Clin. Infect. Dis. 2001, 32:124-129.
36. Kesselring A.M., Wit F.W., Sabin C.A., Lundgren J.D., Gill M.J., Gatell J.M., Rauch A., Montaner J.S., de Wolf F., Reiss P., Mocroft A. Nevirapine Toxicity Multicohort Collaboration, Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009, 23:1689-1699.
37. Patel S.M., Johnson S., Belknap S.M., Chan J., Sha B.E., Bennett C. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 2004, 35:120-125.
38. Yuan J., Guo S., Hall D., Cammett A.M., Jayadev S., Distel M., Storfer S., Huang Z., Mootsikapun P., Ruxrungtham K., Podzamczer D., Haas D.W. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 2011, 25:1271-1280. the Nevirapine Toxicogenomics Study Team.
39. Vitezica Z.G., Milpied B., Lonjou C., Borot N., Ledger T.N., Lefebvre A., Hovnanian A. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008, 22:540-541.
40. Chantarangsu S., Mushiroda T., Mahasirimongkol S., Kiertiburanakul S., Sungkanuparph S., Manosuthi W., Tantisiriwat W., Charoenyingwattana A., Sura T., Chantratita W., Nakamura Y. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet. Genomics 2009, 19:139-146.
41. Gatanaga H., Yazaki H., Tanuma J., Honda M., Genka I., Teruya K., Tachikawa N., Kikuchi Y., Oka S. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007, 21:264-265.
42. Likanonsakul S., Rattanatham T., Feangvad S., Uttayamakul S., Prasithsirikul W., Tunthanathip P., Nakayama E.E., Shioda T. HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res. Ther. 2009, 6:22.
43. O.A. Adaramoye, O.A. Adesanoye, O.M. Adewumi, O. Akanni, Studies on the toxicological effect of nevirapine, an antiretroviral drug, on the liver, kidney and testis of male Wistar rats, Hum. Exp. Toxicol. (Epub October 25, 2011), in press. http://dx.doi.org/10.1177/0960327111424304.
44. VIRAMUNE (Nevirapine) Physicians' Desk Reference, 63rd ed, Montvale. NJ 2009, 873-881.
45. Lamson M.J., Sabo J.P., MacGregor T.R., Pav J.W., Rowland L., Hawi A., Cappola M., Robinson P. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm. Drug Dispos. 1999, 20:285-291.
46. Mirochnick M., Clarke D.F., Dorenbaum A. Nevirapine: pharmacokinetic considerations in children and pregnant women. Clin. Pharmacokinet. 2000, 39:281-293.
47. Haas D.W., Bartlett J.A., Andersen J.W., Sanne I., Wilkinson G.R., Hinkle J., Rousseau F., Ingram C.D., Shaw A., Lederman M.M., Kim R.B. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin. Infect. Dis. 2006, 43:783-786.
48. Ritchie M.D., Haas D.W., Motsinger A.A., Donahue J.P., Erdem H., Raffanti S., Rebeiro P., George A.L., Kim R.B., Haines J.L., Sterling T.L. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin. Infect. Dis. 2006, 43:779-782.
49. Liptrott N.J., Pushpakom S., Wyen C., Fätkenheuer G., Hoffmann C., Mauss S., Knechten H., Brockmeyer N.H., Hopper-Borge E., Siccardi M., Back D.J., Khoo S.H., Pirmohamed M., Owen A. Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenet. Genomics 2012, 22:10-19. German Competence Network for HIVAIDS.
50. Riska P., Lamson M., MacGregor T., Sabo J., Hattox S., Pav J., Keirns J. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab. Dispos. 1999, 27:895-901.
51. Riska P.S., Joseph D.P., Dinallo R.M., Davidson W.C., Keirns J.J., Hattox S.E. Biotransformation of nevirapine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees. Drug Metab. Dispos. 1999, 27:1434-1447.
52. Erickson D.A., Mather G., Trager W.F., Levy R.H., Keirns J.J. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab. Dispos. 1999, 27:1488-1495.
53. Liu Z., Fan-Havard P., Xie Z., Ren C., Chan K.K. A liquid chromatography/atmospheric pressure ionization tandem mass spectrometry quantitation method for nevirapine and its two oxidative metabolites, 2-hydroxynevirapine and nevirapine 4-carboxylic acid, and pharmacokinetics in baboons. Rapid Commun. Mass Spectrom. 2007, 21:2734-2742.
54. Ren B., Fan-Havard P., Schlabritz-Loutsevitch N., Ling Y., Chan K.K., Liu Z. A sensitive and specific liquid chromatography/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboons. Biomed. Chromatogr. 2010, 24:717-726.
55. Kappelhoff B.S., van Leth F., MacGregor T.R., Lange J., Beijnen J.H., Huitema A.D. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir. Ther. 2005, 10:145-155. 2NN Study Group.
56. Rotger M., Colombo S., Furrer H. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 2005, 15:1-5.
57. Saitoh A., Sarles E., Capparelli E., Aweeka F., Kovacs A., Burchett S.K., Wiznia A., Nachman S., Fenton T., Spector S.A. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007, 21:2191-2199.
58. Mahungu T.W., Smith C., Turner F., Egan D., Youle M., Johnson M.A., Khoo S., Back D.J., Owen A. Cytochrome P450 2B6 516G ->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med. 2009, 10:310-317.
59. Lehr T., Yuan J., Hall D., Zimdahl-Gelling H., Schaefer H.G., Staab A., MacGregor T.R., Jayadev S. Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine. Pharmacogenet. Genomics 2011, 21:721-730.
60. S.A. Pereira, M.M. Marques, U. Caixas, E.C. Monteiro, F.A. Beland, A.M.M. Antunes, Understanding the molecular basis for the hazards associated with nevirapine treatment, in: L.V. Berhardt (Ed.), Advances in Medicine and Biology, Vol. 44, Nova Science Publisher, Inc., Hauppauge, NY, in press.
61. Claes P., Wintzen M., Allard S., Simons P., De Coninck A., Lacor P. Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully with a combination of intravenous immunoglobulins and N-acetylcysteine. Eur. J. Intern. Med. 2004, 15:255-258.
62. de Rosa S.C., Zaretsky M.D., Dubs J.G., Roederer M., Anderson M., Green A., Mitra D., Watanabe N., Nakamura H., Tjioe I., Deresinski S.C., Moore W.A., Ela S.W., Parks D., Herzenberg L.A. N-acetylcysteine replenishes glutathione in HIV infection. Eur. J. Clin. Invest. 2000, 30:915-929.
63. Takakusa H., Masumoto H., Yukinaga H., Makino C., Nakayama S., Okazaki O., Sudo K. Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity. Drug Metab. Dispos. 2008, 36:1770-1779.
64. Chen J., Mannargudi M.B., Xu L., Uetrecht J. Demonstration of the metabolic pathway responsible for nevirapine induced skin rash. Chem. Res. Toxicol. 2008, 21:1862-1870.
65. Shenton J.M., Teranishi M., Abu-Asab M.S., Yager J.A., Uetrecht J.P. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem. Res. Toxicol. 2003, 16:1078-1089.
66. Shenton J.M., Popovic M., Chen J., Masson M.J., Uetrecht J.P. Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat. Chem. Res. Toxicol. 2005, 18:1799-1813.
67. Popovic M., Caswell J.L., Mannargudi B., Shenton J.M., Uetrecht J.P. Study of the sequence of events involved in nevirapine-induced skin rash in Brown Norway rats. Chem. Res. Toxicol. 2006, 19:1205-1214.
68. Meisheri K.D., Johnson G.A., Puddington L. Enzymatic and non-enzymatic sulfation mechanisms in the biological actions of minoxidil. Biochem. Pharmacol. 1993, 45:271-279.
69. Merk H.F. Drug skin metabolites and allergic drug reactions. Curr. Opin. Allergy Clin. Immunol. 2009, 9:311-315.
70. Wen B., Chen Y., Fitch W.L. Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4. Drug Metab. Dispos. 2009, 37:1557-1562.
71. Walubo A., Barr S., Abraham A.M. Rat CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity. Methods Find. Exp. Clin. Pharmacol. 2006, 28:423-431.
72. Srivastava A., Lian L.Y., Maggs J.L., Chaponda M., Pirmohamed M., Williams D.P., Park B.K. Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries. Drug Metab. Dispos. 2010, 38:122-132.
73. Glatt H. Sulfation and sulfotransferases 4. Bioactivation of mutagens via sulfation. FASEB J. 1997, 11:314-321.
74. Bolton J., Trush M.A., Penning T.M., Dryhurst G., Monks T.J. Role of quinones in toxicology. Chem. Res. Toxicol. 2000, 13:135-160.
75. Monks T.J., Jones D.C. The metabolism and toxicity of quinones, quinonimines and quinone-thioethers. Curr. Drug Metab. 2002, 3:425-438.
76. Antunes A.M.M., Novais D.A., Ferreira da Silva J.L., Santos P.P., Oliveira M.C., Beland F.A., Marques M.M. Synthesis and oxidation of 2-hydroxynevirapine, a metabolite of the HIV reverse transcriptase inhibitor nevirapine. Org. Biomol. Chem. 2011, 9:7822-7835.
77. Porubek D., Rundgren M., Larsson R., Albano E., Ross D., Nelson S.D., Moldéus P. Quinone imines as biological relevant intermediates. Adv. Exp. Med. Biol. 1986, 197:631-644.
78. Svensson B.E. Abilities of peroxidases to catalyse peroxidase-oxidase oxidation of thiols. Biochem. J. 1988, 256:757-762.
79. Moura M.D., Senna M.I., Madureira D.F., Fonseca L.M., Mesquita R.A. Oral adverse effects due to the use of nevirapine. J. Contemp. Dent. Pract. 2008, 9:84-90.
80. Scully C., Diz Dios P. Orofacial effects of antiretroviral therapies. Oral Dis. 2001, 7:205-210.
81. Hall D.B., MacGregor T.R. Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolites. HIV Clin. Trials 2007, 8:391-399.
82. Almond L.M., Boffito M., Hoggard P.G., Bonora S., Raiteri R., Reynolds H.E., Garazzino S., Sinicco A., Khoo S.H., Back D.J., Di Perri G. The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res. Hum. Retroviruses 2004, 20:716-722.
83. de Requena D.G., Jiménez-Nácher I., Soriano V. Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations. AIDS Res. Hum. Retroviruses 2005, 21:555-559.
84. Cammett A.M., MacGregor T.R., Wruck J.M., Felizarta F., Miailhes P., Mallolas J., Piliero P.J. Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis. Antimicrob. Agents Chemother. 2009, 53:4147-4152.
85. Barreiro P., Rodríguez-Novoa S., Labarga P., Ruiz A., Jiménez-Nácher I., Martín-Carbonero L., Gonzalez-Lahoz J., Soriano V. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J. Infect. Dis. 2007, 195:973-979.
86. Regazzi M., Villani P., Seminari E., Ravasi G., Cusato M., Marubbi F., Meneghetti G., Maserat R. Sex differences in nevirapine disposition in HIV-infected patients. AIDS 2003, 17:2399-2400.
87. Rodríguez-Novoa S., Barreiro P., Redón A., Jiménez-Nacher I., González-Lahoz J., Soriano V. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin. Infect. Dis. 2005, 40:1358-1361.
88. Sulkowski M.S., Thomas D.L., Mehta S.H., Chaisson R.E., Moore R.D. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002, 35:182-189.
89. Park B.K., Kitteringham N.R., Maggs J.L., Pirmohamed M., Williams D.P. The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 2005, 45:177-202.
90. Farmer P.B. DNA and protein adducts as markers of genotoxicity. Toxicol. Lett. 2004, 149:3-9.
91. Antunes A.M.M., Godinho A.L., Martins I.L., Justino G.C., Beland F.A., Marques M.M. Amino acid adduct formation by the nevirapine metabolite, 12-hydroxynevirapine-a possible factor in nevirapine toxicity. Chem. Res. Toxicol. 2010, 23:888-899.
92. Antunes A.M.M., Duarte M.P., Santos P.P., da Costa G.Gamboa, Heinze T.M., Beland F.A., Marques M.M. Synthesis and characterization of DNA adducts from the HIV reverse transcriptase inhibitor nevirapine. Chem. Res. Toxicol. 2008, 21:1443-1456.
93. Seutter-Berlage F., van Dorp H.L., Kosse H.G., Henderson P.T. Urinary mercapturic acid excretion as a biological parameter of exposure to alkylating agents. Int. Arch. Occup. Environ. Health 1977, 39:45-51.
94. Rothschild M.A., Oratz M., Schreiber S.S. Albumin synthesis. N. Engl. J. Med. 1972, 286:748-757.
95. Antunes A.M.M., Godinho A.L.A., Martins I.L., Oliveira M.C., Gomes R.A., Coelho A.V., Beland F.A., Marques M.M. Protein adducts as prospective biomarkers of nevirapine toxicity. Chem. Res. Toxicol. 2010, 23:1714-1725.
96. Törnqvist M., Fred C., Haglund J., Helleberg H., Paulsson B., Rydberg P. Protein adducts: quantitative and qualitative aspects of their formation, analysis and application. J. Chromatogr. B 2002, 778:279-308.
97. Boysen G., Georgieva N.I., Upton P.B., Walker V.E., Swenberg J.A. N-terminal globin adducts as biomarkers for formation of butadiene derived epoxides. Chem. Biol. Interact. 2007, 166:84-92.
98. Chevolleau S., Jacques C., Canlet C., Tulliez J., Debrauwer L. Analysis of hemoglobin adducts of acrylamide and glycidamide by liquid chromatography-electrospray ionization tandem mass spectrometry, as exposure biomarkers in French population. J. Chromatogr. A 2007, 1167:125-134.
99. Angerer J., Ewers U., Wilhelm M. Human biomonitoring: state of the art. Int. J. Hyg. Environ. Health 2007, 210:201-228.
100. Rakhmanina N.Y., van den Anker J.N. Efavirenz in the therapy of HIV infection. Expert Opin. Drug Metab. Toxicol. 2010, 6:95-103.
101. Pérez-Molina J.A. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin. Trials 2002, 3:279-286.
102. Kenedi C.A., Goforth H.W. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 2011, 15:1803-1818.
103. Welz T., Childs K., Ibrahim F., Poulton M., Taylor C.B., Moniz C.F., Post F.A. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010, 24:1923-1928.
104. Cavalcante G.I.T., Capistrano V.L.M., Cavalcante F.S.D., Vasconcelos S.M.M., Macêdo D.S., Sousa F.C.F., Woods D.J., Fonteles M.M.F. Implications of efavirenz for neuropsychiatry: a review. Int. J. Neurosci. 2010, 120:739-745.
105. Fumaz C.R., Tuldrà A., Ferrer M.J., Paredes R., Bonjoch A., Jou T., Negredo E., Romeu J., Sirera G., Tural C., Clotet B. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J. Acquir. Immune Defic. Syndr. 2002, 29:244-253.
106. Muñoz-Moreno J.A., Fumaz C.R., Ferrer M.J., González-García M., Moltó J., Negredo E., Clotet B. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. AIDS Rev. 2009, 11:103-109.
107. Vrouenraets S.M.E., Wit F.W.N.M., van Tongeren J., Lange J.M.A. Efavirenz: a review. Expert Opin. Pharmacother. 2007, 8:851-871.
108. Ciccarelli N., Fabbiani M., Di Giambenedetto S., Fanti I., Baldonero E., Bracciale L., Tamburrini E., Cauda R., De Luca A., Silveri M.C. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011, 76:1403-1409.
109. Lochet P., Peyrière H., Lotthé A., Mauboussin J.M., Delmas B., Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003, 4:62-66.
110. Fumaz C.R., Muñoz-Moreno J.A., Moltó J., Ferrer M.J., Sirera G., Pérez-Alvarez N., Gómez G., Burger D., Clotet B. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J. Acquir. Immune Defic. Syndr. 2005, 38:560-565.
111. Spire B., Carrieri P., Garzot M.-A., L'henaff M., Obadia Y., TRT-5 Group Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care 2004, 16:558-564.
112. Pilon A.A., Lum J.J., Sanchez-Dardon J., Phenix B.N., Douglas R., Badley A.D. Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor. Antimicrob. Agents Chemother. 2002, 46:2687-2691.
113. Blas-García A., Apostolova N., Ballesteros D., Monleón D., Morales J.M., Rocha M., Victor V.M., Esplugues J.V. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 2010, 52:115-125.
114. Apostolova N., Gómez-Sucerquia L.J., Moran A., Alvarez A., Blas-García A., Esplugues J.V. Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. Br. J. Pharmacol. 2010, 160:2069-2084.
115. Apostolova N., Blas-García A., Ballesteros D., González Y., Morán A., Gómez-Sucerquia L.J., Esplugues J.V. Clinical concentrations of efavirenz (EFV) reduce cellular proliferation and viability in several human cell lines. Abstracts of the Ninth International Congress on Drug Therapy in HIV Infections. J. Int. AIDS Soc. 2008, 11(Suppl. 1):P161.
116. Streck E.L., Ferreira G.K., Scaini G., Rezin G.T., Gonçalves C.L., Jeremias I.C., Zugno A.I., Ferreira G.C., Moreira J., Fochesato C.M., Romão P.R.T. Non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine inhibit cytochrome C oxidase in mouse brain regions. Neurochem. Res. 2011, 36:962-966.
117. Bristol-Myers Squibb Pharmaceuticals Ltd Efavirenz: summary of product characteristics. European Medicines Evaluation Agency 2009, (accessed January 8, 2012). http://emc.medicines.org.uk/medicine/11284/SPC/Sustiva+600+mg+Film-Coated+Tablets/.
118. Smith P.F., DiCenzo R., Morse G.D. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin. Pharmacokinet. 2001, 40:893-905.
119. Best B.M., Koopmans P.P., Letendre S.L., Capparelli E.V., Rossi S.S., Clifford D.B., Collier A.C., Gelman B.B., Mbeo G., McCutchan J.A., Simpson D.M., Haubrich R., Ellis R., Grant I. Charter Group, Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J. Antimicrob. Chemother. 2011, 66:354-357.
120. di Iulio J., Fayet A., Arab-Alameddine M., Rotger M., Lubomirov R., Cavassini M., Furrer H., Günthard H.F., Colombo S., Csajka C., Eap C.B., Decosterd L.A., Telenti A. In vivo analysis of efavirenz metabolism in individuals with impaired CYP 2A6 function. Pharmacogenet. Genomics 2009, 19:300-309. Swiss HIV Cohort Study.
121. Arab-Alameddine M., Di Iulio J., Buclin T., Rotger M., Lubomirov R., Cavassini M., Fayet A., Décosterd L.A., Eap C.B., Biollaz J., Telenti A., Csajka C. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin. Pharmacol. Ther. 2009, 85:485-494. Swiss HIV Cohort Study.
122. Kwara A., Lartey M., Sagoe K.W.C., Kenu E., Court M.H. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 2009, 23:2101-2106.
123. Kwara A., Lartey M., Sagoe K.W., Rzek N.L., Court M.H. CYP2B6 (c.516G->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br. J. Clin. Pharmacol. 2009, 67:427-436.
124. Motsinger A.A., Ritchie M.D., Shafer R.W., Robbins G.K., Morse G.D., Labbe L., Wilkinson G.R., Clifford D.B., D'Aquila R.T., Johnson V.A., Pollard R.B., Merigan T.C., Hirsch M.S., Donahue J.P., Kim R.B., Haas D.W. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet. Genomics 2006, 16:837-845.
125. Burger D., van der Heiden I., la Porte C., van der Ende M., Groeneveld P., Richter C., Koopmans P., Kroon F., Sprenger H., Lindemans J., Schenk P., van Schaik R. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP 2B6 polymorphism. Br. J. Clin. Pharmacol. 2006, 61:148-154.
126. Pereira S.A., Branco T., Caixas U., Côrte-Real R.M., Germano I., Lampreia L., Monteiro E.C. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy. Ther. Drug Monit. 2008, 30:60-66.
127. Mukonzo J.K., Nanzigu S., Rekić D., Waako P., Röshammar D., Ashton M., Ogwal-Okeng J., Gustafsson L.L., Aklillu E. HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. Clin. Pharmacokinet. 2011, 50:531-540. Erratum in: Clin. Pharmacokinet. 50 (2011) 624.
128. Stöhr W., Back D., Dunn D., Sabin C., Winston A., Gilson R., Pillay D., Hill T., Ainsworth J., Pozniak A., Leen C., Bansi L., Fisher M., Orkin C., Anderson J., Johnson M., Easterbrook P., Gibbons S., Khoo S. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir. Ther. 2008, 13:675-685. Liverpool TDM Database, UK CHIC StudyUK CHIC Study.
129. Pereira S.A., Caixas U., Branco T., Germano I., Lampreia F., Papoila A.L., Monteiro E.C. Efavirenz concentrations in HIV-infected patients with and without viral hepatitis. Br. J. Clin. Pharmacol. 2008, 66:551-555.
130. Marzolini C., Telenti A., Decosterd L.A., Greub G., Biollaz J., Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001, 15:71-75.
131. Gutiérrez F., Navarro A., Padilla S., Antón R., Masiá M., Borrás J., Martín-Hidalgo A. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin. Infect. Dis. 2005, 41:1648-1653.
132. Kappelhoff B.S., van Leth F., Robinson P.A., MacGregor T.R., Baraldi E., Montella F., Uip D.E., Thompson M.A., Russell D.B., Lange J.M., Beijnen J.H., Huitema A.D. Are adverse events of nevirapine and efavirenz related to plasma concentrations?. Antivir. Ther. 2005, 10:489-498.
133. van Luin M., Bannister W.P., Mocroft A., Reiss P., Di Perri G., Peytavin G., Molto J., Karlson A., Castagna A., Beniowski M., Lundgren J.D., Burger D.M. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. Antivir. Ther. 2009, 14:75-83. EuroSIDA Study Group.
134. van Luin M., Gras L., Richter C., van der Ende M.E., Prins J.M., de Wolf F., Burger D.M., Wit F.W. Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations. J. Acquir. Immune Defic. Syndr. 2009, 52:240-245.
135. Read T.R., Carey D., Mallon P., Mijch A., Goodall R., Hudson F., Wand H., Emery S. Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. AIDS 2009, 23:2222-2223.
136. Mutlib A.E., Chen H., Nemeth G.A., Markwalder J.A., Seitz S.P., Gan L.S., Christ D.D. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab. Dispos. 1999, 27:1319-1333.
137. Ward B.A., Gorski J.C., Jones D.R., Hall S.D., Flockhart D.A., Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 2003, 306:287-300.
138. Desta Z., Saussele T., Ward B., Blievernicht J., Li L., Klein K., Flockhart D.A., Zanger U.M. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 2007, 8:547-558.
139. Ogburn E.T., Jones D.R., Masters A.R., Xu C., Guo Y., Desta Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 2010, 38:1218-1229.
140. Wyen C., Hendra H., Siccardi M., Platten M., Jaeger H., Harrer T., Esser S., Bogner J.R., Brockmeyer N.H., Bieniek B., Rockstroh J., Hoffmann C., Stoehr A., Michalik C., Dlugay V., Jetter A., Knechten H., Klinker H., Skaletz-Rorowski A., Fätkenheuer G., Egan D., Back D.J., Owen A. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J. Antimicrob. Chemother. 2011, 66:2092-2098. German Competence Network for HIV/AIDS Coordinators.
141. Ribaudo H.J., Liu H., Schwab M., Schaeffeler E., Eichelbaum M., Motsinger-Reif A.A., Ritchie M.D., Zanger U.M., Acosta E.P., Morse G.D., Gulick R.M., Robbins G.K., Clifford D., Haas D.W. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J. Infect. Dis. 2010, 202:717-722.
142. Saitoh A., Fletcher C.V., Brundage R., Alvero C., Fenton T., Hsia K., Spector S.A. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J. Acquir. Immune Defic. Syndr. 2007, 45:280-285.
143. Haas D.W., Ribaudo H.J., Kim R.B., Tierney C., Wilkinson G.R., Gulick R.M., Clifford D.B., Hulgan T., Marzolini C., Acosta E.P. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004, 18:2391-2400.
144. Rotger M., Tegude H., Colombo S., Cavassini M., Furrer H., Décosterd L., Blievernicht J., Saussele T., Günthard H.F., Schwab M., Eichelbaum M., Telenti A., Zanger U.M. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 2007, 81:557-566.
145. Wang J., Sonnerborg A., Rane A., Josephson F., Lundgren S., Ståhle L., Ingelman-Sundberg M. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics 2006, 16:191-198.
146. Bae S.K., Jeong Y.-J., Lee C., Liu K.-H. Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites. Xenobiotica 2011, 41:437-444.
147. Cho D.-Y., Ogburn E.T., Jones D., Desta Z. Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz. Antimicrob. Agents Chemother. 2011, 55:1504-1509.
148. Elens L., Vandercam B., Yombi J.C., Lison D., Wallemacq P., Haufroid V. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics 2011, 11:1223-1234.
149. Belanger A.S., Caron P., Harvey M., Zimmerman P.A., Mehlotra R.K., Guillemette G. Glucuronidation of the antiretroviral drug efavirenz (EFV) by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine (AZT). Drug Metab. Dispos. 2009, 37:1793-1796.
150. Mutlib A.E., Gerson R.J., Meunier P.C., Haley P.J., Chen H., Gan L.S., Davies M.H., Gemzik B., Christ D.D., Krahn D.F., Markwalder J.A., Seitz S.P., Robertson R.T., Miwa G.T. The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol. Appl. Pharmacol. 2000, 169:102-113.
151. Fellay J., Marzolini C., Meaden E.R., Back D.J., Buclin T., Chave J.P., Decosterd L.A., Furrer H., Opravil M., Pantaleo G., Retelska D., Ruiz L., Schinkel A.H., Vernazza P., Eap C.B., Telenti A. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002, 359:30-36. Swiss HIV Cohort Study.
152. Yimer G., Ueda N., Habtewold A., Amogne W., Suda A., Riedel K.D., Burhenne J., Aderaye G., Lindquist L., Makonnen E., Aklillu E. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One 2011, 6:e27810.
153. Bumpus N., Kent U., Hollenberg P. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. J. Pharmacol. Exp. Ther. 2006, 318:345-351.
154. LoPachin R.M., Barber D.S. Synaptic cysteine sulfhydryl groups as targets of electrophilic neurotoxicants. Toxicol. Sci. 2006, 94:240-255.
155. Bumpus N.N. Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes. Toxicol. Appl. Pharmacol. 2011, 257:227-234.
156. Bolton J.L. Quinoids, quinoid radicals, and phenoxyl radicals formed from estrogens and antiestrogens. Toxicology 2002, 177:55-65.
157. Ngaimisi E., Mugusi S., Minzi O.M., Sasi P., Riedel K.-D., Suda A., Ueda N., Janabi M., Mugusi F., Haefeli W.E., Burhenne J., Aklillu E. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin. Pharmacol. Ther. 2010, 88:676-684.
158. Barrett J.S., Joshi A.S., Chai M., Ludden T.M., Fiske W.D., Pieniaszek H.J. Population pharmacokinetic meta-analysis with efavirenz. Int. J. Clin. Pharmacol. Ther. 2002, 40:507-519.
159. Faucette S.R., Zhang T.C., Moore R., Sueyoshi T., Omiecinski C.J., LeCluyse E.L., Negishi M., Wang H. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP 2B6 and CYP 3A4 inducers. J. Pharmacol. Exp. Ther. 2007, 320:72-80.
160. Mouly S., Lown K.S., Kornhauser D., Joseph J.L., Fiske W.D., Benedek I.H., Watkins P.B. Hepatic but not intestinal CYP 3A4 displays dose-dependent induction by efavirenz in humans. Clin. Pharmacol. Ther. 2002, 72:1-9.
161. Miksys S., Lerman C., Shields P.G., Mash D.C., Tyndale R.F. Smoking, alcoholism and genetic polymorphisms alter CYP 2B6 levels in human brain. Neuropharmacology 2003, 45:122-132.
162. Khokhar J.Y., Tyndale R.F. Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects. Neuropsychopharmacology 2011, 36:692-700.
163. Madruga J.V., Cahn P., Grinsztejn B., Haubrich R., Lalezari J., Mills A., Pialoux G., Wilkin T., Peeters M., Vingerhoets J., de Smedt G., Leopold L., Treiglio R., Woodfall B., on behalf of the DUET-1 study group Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370:29-38.
164. Tibotec Therapeutics, Intelence® (etravirine) tablets prescribing information 2010, (accessed January 8, 2012). http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022187s003lbl.pdf.
165. Montaner J., Yeni P., Clumeck N.N., Fätkenheuer G., Gatell J., Hay P., Seminari E., Peeters M.P., Schöller-Gyüre M., Simonts M., Woodfall B. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection. Clin. Infect. Dis. 2008, 47:969-978. TMC125-C203 Study Group.
166. Kakuda T.N., Wade J.R., Snoeck E., Vis P., Schöller-Gyüre M., Peeters M.P., Corbett C., Nijs S., Vingerhoets J., Leopold L., De Smedt G., Woodfall B.J., Hoetelmans R.M. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. Clin. Pharmacol. Ther. 2010, 88:695-703.
167. Schöler-Gyüre M., Kakuda T.N., Raoof A., De Smedt G., Hoetelmans R.M.W. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin. Pharmacokinet. 2009, 48:561-574.
168. Seminari E., Castagna A., Lazzarin A. Etravirine for the treatment of HIV infections. Expert Rev. Anti Infect. Ther. 2008, 4:427-433.
169. Schöler-Gyüre M., Kakuda T.N., Stevens T., Aharchi F., De Smedt G., Peeters M., Hoetelmans R.M.W. Effect of etravirine on cytochrome P450 isozymes assessed by the Cooperstown 5+1 cocktail 2008, (accessed January 8, 2012). http://www.medadvocates.org/resources/conferences/icaac/48/etravirine/ICAAC_IDSA%20_Sch%F6ller-Gy%FCre_201008.pdf.
170. Lubomirov R., Rotger M., Fayet A., Martinez R., Colombo S., di Iulio J., Decosterd L.A., Csajka C., Telenti A. the Swiss HIV Cohort Study, Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals 2011, (accessed January 8, 2012). http://www.retroconference.org/2011/PDFs/479.pdf.
171. Yanakakis L., Bumpus N.N. Time-dependent cytochrome P450-mediated metabolism of etravirine in primary human hepatocytes, P260 2011, (accessed January 8, 2012). http://issx.confex.com/issx/17NA/webprogram/Paper25697.html.
172. Zembruski N.C., Haefeli W.E., Weiss J. Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob. Agents Chemother. 2011, 55:1282-1284.
173. Brown K.C., Paul S., Kashuba A.D. Drug interactions with new and investigational antiretrovirals. Clin. Pharmacokinet. 2009, 48:211-241.
174. Kakuda T.N., Schöller-Gyüre M., Hoetelmans R.M. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antivir. Ther. 2010, 15:817-829.
175. Schöller-Gyüre M., van den Brink W., Kakuda T.N., Woodfall B., De Smedt G., Vanaken H., Stevens T., Peeters M., Vandermeulen K., Hoetelmans R.M.W. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J. Clin. Pharmacol. 2008, 48:322-329.
176. Testa B., Kramer S.D. The biochemistry of drug metabolism-an introduction: part 4. Reactions of conjugation and their enzymes. Chem. Biodivers. 2008, 5:2171-2336.
177. Goggin M., Anderson C., Park S., Swenberg J., Walker V., Tretyakova N. Quantitative high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry analysis of the adenine-guanine cross-links of 1,2,3,4-diepoxybutane in tissues of butadiene-exposed B6C3F1 mice. Chem. Res. Toxicol. 2008, 21:1163-1170.
178. Lu D., Peterson L.A. Identification of furan metabolites derived from cysteine-cis-2-butene-1,4-dial-lysine, cross-links. Chem. Res. Toxicol. 2010, 23:142-151.
179. Cohen C.J., Andrade-Villanueva J., Clotet B., Fourie J., Johnson M.A., Ruxrungtham K., Wu H., Zorrilla C., Crauwels H., Rimsky L.T., Vanveggel S., Boven K., on behalf of the THRIVE study group Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011, 378:229-237.
180. Gilead Sciences, COMPLERA® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets, Foster City 2011, (accessed January 8, 2012). http://www.gilead.com/pdf/complera_pi.pdf.
181. Janssen P.A., Lewi P.J., Arnold E., Daeyaert F., de Jonge M., Heeres J., Koymans L., Vinkers M., Guillemont J., Pasquier E., Kukla M., Ludovici D., Andries K., de Béthune M.P., Pauwels R., Das K., Clark A.D., Frenke Y.V., Hughes S.H., Medaer B., De Knaep F. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J. Med. Chem. 2005, 48:1901-1909.
182. Garvey L., Winston A. Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. Expert Opin. Investig. Drugs 2009, 18:1035-1041.
183. Crauwels H.M, van Heeswijk R.P.G., Stevens T., Stevens M., Buelens A., Boven K., Hoetelmans R.M.W. Hoetelmans, The effect of TMC278, a next generation NNRTI, on CYP3A activity in vivo 2009, Drug Report (abstract P28), page 3., (accessed June 18, 2012). http://www.hiv-druginteractions.org/data/NewsItem/72_10%20PKW%20Amsterdam.pdf.
184. Lachau-Durand R.N.V.S., Mamidi F., Cuyckens V., Michlova G., Mannens A., Raoof K. Absorption, metabolism and excretion of TMC278, an NNRTI, after a single oral dose of 150mg in healthy male volunteers, EACS 2009, (accessed January 8, 2012). http://www.natap.org/2009/EACS/EACS_57a.htm.
185. O'Brien P.J., Siraki A.G., Shangari N. Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit. Rev. Toxicol. 2005, 35:609-662.